BPC-157 vs ARA-290: Purity, Cost & COA Data

BPC-157 and ARA-290 are not interchangeable reference materials, and the practical differences show up in the certificate of analysis long before they show up anywhere else. BPC-157 is a 15-residue pentadecapeptide (GEPPPGKPADDAGLV, MW ~1419.5 Da) that is straightforward to synthesize by standard Fmoc solid-phase methods and routinely lands at 98%+ HPLC purity for roughly $18–$45 per 5 mg vial at research quantities. ARA-290 (cibinetide) is an 11-residue peptide (QEQLERALNSS, MW ~1257.4 Da) derived from the helix B region of erythropoietin, produced in far lower global volume, and typically prices at $60–$180 per 5 mg — a 3–4x premium driven by demand scale, not synthesis difficulty. If you are comparing the two as catalog items, purity documentation and lot traceability matter more than headline price.

The identity problem is different for each peptide

BPC-157 has a sequence quirk that makes analytical verification unusually important: the PPPG run at positions 3–6 and the ADDAG stretch at 9–13 both create characteristic deletion products during synthesis. A single proline deletion drops the mass by 97.1 Da; a glycine deletion by 57.0 Da. On a low-resolution ESI-MS trace with a 0.5 Da window, those are trivially resolvable. On a supplier's PDF that shows only a single reported mass with no spectrum, they are invisible.

ARA-290's failure modes cluster elsewhere. The C-terminal SS dipeptide and the internal N-S sequence create deamidation risk at the asparagine residue — a +0.98 Da shift to aspartate that many suppliers' MS resolution simply cannot separate from the parent peak. Detecting it requires either high-resolution MS (≤5 ppm mass accuracy) or an HPLC method with enough resolving power to separate the isoaspartate variant, which usually means a shallower gradient than the 5–95% acetonitrile-over-20-minutes default most vendors run.

A COA that reports "98.7% purity" without the chromatogram, the gradient, the column, and the detection wavelength is a number, not a document.

What a usable certificate of analysis contains

Ask for these before purchase, for either peptide:

• The actual RP-HPLC chromatogram, not a summary table — C18 column, 4.6 x 250 mm or 2.1 x 150 mm, particle size stated (3 µm or 5 µm), with the gradient profile and flow rate (typically 1.0 mL/min analytical, 0.3 mL/min for narrow-bore)
• Detection wavelength, which should be 214–220 nm for peptide bond absorbance. A COA reporting only 280 nm is nearly meaningless for BPC-157, which contains zero tryptophan or tyrosine and therefore has almost no 280 nm chromophore
• Mass spectrometry data with the observed m/z series, not just a calculated monoisotopic mass. For BPC-157 expect [M+2H]²⁺ near 710.8; for ARA-290, near 629.7
• Net peptide content separate from HPLC purity — a 99% pure lyophilate can be 65–80% peptide by mass, the balance being TFA counterion and residual water
• Lot number tied to a specific synthesis date, not a generic catalog SKU

That net peptide content distinction accounts for more inter-supplier variance than purity does. Two vials both labeled "5 mg, 99% pure" can differ by 20% in actual peptide mass if one reports gross lyophilate weight and the other reports net peptide. At $150 per vial for ARA-290, that is a $30 discrepancy per unit that never appears on the invoice. Our approach to documentation is described on the quality page.

Stability and storage: where the two genuinely diverge

Lyophilized BPC-157 stored at -20 °C in a sealed vial with desiccant is stable for 24–36 months by most suppliers' published data. At 4 °C, that window shortens to roughly 6–12 months. At ambient 20–25 °C, BPC-157 is relatively forgiving for short transit periods — a 3–5 day shipment without cold packs is unlikely to produce measurable degradation, which is why many suppliers ship it ambient. See shipping for handling specifics.

ARA-290 is less forgiving. The deamidation-prone Asn and the two adjacent serines mean that lyophilized material held above 8 °C shows a measurably faster rise in the +1 Da variant. Suppliers who take this seriously will state a -20 °C storage condition with a 12–24 month assigned shelf life rather than the 36-month figure applied to BPC-157, and will ship on cold packs. If a vendor quotes identical storage and stability specs for both peptides, they are copying a template rather than reporting data.

Neither peptide should be assumed stable in solution. Published aqueous stability for small linear peptides of this class is on the order of days at 4 °C, not weeks, and that is a property of the molecule — not something a supplier can improve.

When neither purchase is worth making

This is where most comparison pages stop being useful, so plainly:

• If you have no analytical capability in-house, buying ARA-290 at $60–$180 per vial is mostly buying a story. You cannot verify the deamidation state, you cannot confirm net peptide content, and you are trusting a PDF. If your protocol does not include at minimum an incoming HPLC check or a third-party assay costing $150–$400 per lot, the premium over BPC-157 buys you nothing you can demonstrate.
• If your study design does not distinguish the two mechanisms, do not buy both. A large fraction of side-by-side purchases are curiosity, not experimental design. Two peptides in a study with no differentiating readout produces two ambiguous datasets instead of one clean one.
• Single-vial purchases are the worst value in this category. Analytical characterization costs the same whether you buy 1 vial or 40. Spreading a $300 third-party verification across one $150 vial doubles your effective cost; spreading it across a 20-vial lot adds $15 per vial. If you are not buying at wholesale lot scale, consider whether the study is ready to run at all.
• ARA-290's thinner supply base is a real scheduling risk. BPC-157 is manufactured by dozens of contract facilities; ARA-290 by a much smaller number. Lead times of 4–8 weeks on ARA-290 restocks are common versus 3–10 days for BPC-157. If your work has a fixed timeline, that gap matters more than the price difference.
• Lot-to-lot consistency will not hold across suppliers. Two 98% pure lots from different manufacturers can carry entirely different 2% impurity profiles. If your work spans 12–18 months, buy enough from a single lot to cover it, or accept that you have introduced a variable.
• If your institution has not confirmed the material's regulatory classification for your setting, resolve that before ordering. See research use only.

The cost math nobody publishes

A realistic annualized comparison for a small lab running a 12-month program:

| Line item | BPC-157 | ARA-290 |

|---|---|---|

| 20 x 5 mg vials | $360–$900 | $1,200–$3,600 |

| Third-party HPLC/MS verification, 1 lot | $150–$400 | $200–$450 |

| Cold-chain shipping surcharge | $0–$35 | $35–$75 |

| Effective cost per mg (verified) | $5.10–$13.35 | $14.35–$41.25 |

The verification line is fixed cost. It is 17–40% of a small BPC-157 order and 6–15% of an equivalent ARA-290 order — which inverts the usual intuition. Verification is proportionally cheaper on the more expensive peptide, and proportionally punishing on small BPC-157 buys. That argues for consolidating BPC-157 orders into fewer, larger lots.

Qualifying the supplier, not the molecule

Both peptides are commodity-synthesizable. The variable is the vendor. Concrete checks:

• Request a COA for a specific lot you can buy today, not a representative example. Vendors who cannot produce this are reselling unlabeled bulk.
• Compare the reported retention time against your own run. A 0.3-minute shift on a matched method is normal; a 2-minute shift means a different method or a different compound.
• Ask how many distinct manufacturing sources supply their ARA-290. "One" is an honest answer and tells you your continuity risk.
• Ask what their retest interval is. A supplier that reassays retained samples at 12 and 24 months has stability data; one that assigns a shelf life by convention does not.
• Check the returns terms before ordering — analytical discrepancies are a legitimate return reason and the policy should say so.

Comparative reviews of suppliers across this category are collected in the library, including a high purity peptides review and notes on quality research chemicals suppliers.

The short version

BPC-157 is cheap, well-supplied, analytically simple, and forgiving in transit — its risk is that low price attracts low-documentation vendors, and its proline/glycine deletion products hide easily behind a summary COA. ARA-290 costs 3–4x more, has a narrower supply base with 4–8 week lead times, degrades measurably faster above 8 °C, and carries a deamidation failure mode that low-resolution MS cannot detect. Choose based on what your analytical setup can actually verify. If the answer is "nothing," fix that before you fix your shopping list. Questions about specific lots go through contact.

---

Supplied strictly for in-vitro laboratory research by qualified researchers and institutions. Not a drug, food, cosmetic or dietary supplement. Not for human or veterinary consumption. Not evaluated by the FDA.